Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China SXT Pharmaceuticals has the GF Score of 40, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes China SXT Pharmaceuticals
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
China SXT Pharmaceuticals (FRA:2RY1) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
China SXT Pharmaceuticals GF Score Related Terms
FRA:2RY1 vs CABR, BFRI, BIOE: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's GF Score distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's GF Score falls into.
China SXT Pharmaceuticals (FRA:2RY1) has a GF Score of 40 as of Jul. 25, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on China SXT Pharmaceuticals and its competitors. This is near median its historical median of 37.00. Over the past decade, China SXT Pharmaceuticals' GF Score has ranged from 20.00 to 58.00.
Is China SXT Pharmaceuticals' GF Score too high?
China SXT Pharmaceuticals' current GF Score of 40 is near median its 10-year median of 37.00. Over the past 10 years, this metric has ranged from a low of 20.00 to a high of 58.00. Overall, China SXT Pharmaceuticals has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' GF Score compare to CABR and BFRI?
China SXT Pharmaceuticals' GF Score of 40 can be compared against companies in the Drug Manufacturers industry. Historically, China SXT Pharmaceuticals' own GF Score has ranged from 20.00 to 58.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on China SXT Pharmaceuticals and its competitors. China SXT Pharmaceuticals's current GF Score is 40, which is near median its own 10-year median of 37.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (FRA:2RY1) has a current GF Score of 40. The stock's GF Value™ is €1.16, compared to a current price of €0.04 — trading 96.9% below its estimated fair value. The current GF Score is 40, which is near median its 10-year median of 37.00. China SXT Pharmaceuticals' overall GF Score™ is 40/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For China SXT Pharmaceuticals (FRA:2RY1), the current GF Score is 40 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China SXT Pharmaceuticals (FRA:2RY1) Overvalued in 2026?
Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued.
The current stock price of €0.04 is trading 96.9% below its estimated GF Value™ of €1.16.
Key valuation signals for FRA:2RY1:
GF Score: 40 (near median its 10-year median of 37.00)
GF Value™: €1.16 vs. price of €0.04 (96.9% below fair value)
No single metric tells the full story. See the FRA:2RY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
40GF Score
Get the complete analysis for FRA:2RY1
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2RY1 has been successfully added to your 
